TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05266833

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow diaphragmatic breathing
Description: The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Slow diaphragmatic breathing
Description: The curriculum was based on three key breathing components that have been shown to reduce stress in adolescents: slow breathing; diaphragmatic breathing; and extended exhale breathing. Slow breathing entails breathing at a pace slower than normal breathing. Diaphragmatic breathing focuses on breaths starting from the diaphragm or abdominal areas, with abdominal, then lung, then chest expansion during the inhale and a slow, gradual, full release of air in the reverse direction on the exhale. Extended exhale breathing comprises breathing with the exhalation duration longer, often twice as long, as the inhalation.~Two versions of slow diaphragmatic extended exhale breathing were included in this study. For both, participants did the practice while seated comfortably and breathing through the nose, and were guided to increase the inhale and exhale durations over the 5 weeks. Students followed 5-minute videos for each session.
Study: NCT05360862

Intervention type: PROCEDURE
Intervention: Prone positioning session
Description: To perform respiratory measurements before, during and after a prone positioning session.
Study: NCT06462105

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
Description: Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride Liposome Injection；Carboplatin Injection；Serplulimab Injection
Description: Cohort 1: Liposomal irinotecan: 50mg/m2, ivgtt, d1; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.~Cohort 2: Etoposide: 100 mg/m2, ivgtt, d1-3; Carboplatin AUC=5, ivgtt, d1; Serplulimab: 4.5mg/kg, ivgtt, d1; The drug was administered once every three weeks for a total of 4 cycles. After 4 cycles, serplulimab is maintained until disease progression or toxicity becomes intolerable.
Study: NCT05733767

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care (EUC)
Description: Patients randomized to arm 1, enhanced care (EC), will receive the following intervention: 1) referral to the state quitline, 1-800-QUIT-NOW, 2) primary care physician notification of an ongoing quit attempt, and 3) enrolled in an assessment-only text message system. This text message system will assess medication use and self-reported smoking cessation outcomes, but will not provide any counseling, advice, or feedback. Participants in arm 1 will receive a text message at discharge, and then they will receive 1 text assessment at the following time points: day 7, month 1, and month 3.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nurse Practitioner Tobacco Treatment Team (NPT3)
Description: Patients randomized to arm 2, personalized care (PC), will receive a multi-component, multi-disciplinary smoking cessation intervention in addition to usual care. This intervention will include three main interventions. First, a nurse practitioner will assess all patients and then prescribe tailored medications for smoking cessation based on patient preferences. Patients will also then receive a sample ad-lib nicotine replacement therapy (NRT) packet for use as needed to their prescribed medications. Second, a Tobacco Treatment Counselor (TTC) will provide personalized advice, education, and coaching to the patient and encourage medication adherence. Third, patients will be enrolled in a smoking cessation text messaging program designed to maintain motivation, encourage medication adherence, and allow communication with the team. The text message program will last for 6 months and will include assessment at the following time points: day 7, month 1, and month 3.
Study: NCT06290570

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-Lead ECG
Description: A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: 12-Lead ECG
Description: A clinically performed 12-lead ECG tracing within 30 days of the appointment will be obtained from the subject medical record and will be used for AI-ECG analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Apple Smart Watch Single Lead ECG
Description: A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: Apple Smart Watch Single Lead ECG
Description: A single lead ECG tracing will be collected using an Apple Smart Watch and tracing will be used for AI-ECG analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: AliveCor KardiaMobile 6-Lead ECG
Description: A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.

Intervention type: DIAGNOSTIC_TEST
Intervention: AliveCor KardiaMobile 6-Lead ECG
Description: A 6-lead ECG tracing will be collected using an AliveCor KardiaMobile device and tracing will be used for AI-ECG analyses.
Study: NCT00000955

Intervention type: DRUG
Group type: OTHER
Intervention: Tuberculin Purified Protein Derivative
Description: Administered intradermally at 5 TU per 0.1 mL
Study: NCT03734640

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-intensity monitoring strategy
Description: Post-tpa patients will be monitored in a lower intensity with less vital status and neurological assessment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Guideline recommended standard monitoring
Description: Post-tpa patients will be monitored in the usual care monitoring environment
Study: NCT05448885

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Patients receive neoadjuvant therapy with gemcitabine(1000mg per square meter on day 1,8) , cisplatin (25mg per square meter on day 1-3) and tislelizumab(200mg) every three weeks for 2 cycles before radiotherapy, then followed by concurrent IMRT and cisplatin (100mg per square meter) concurrent every three weeks during radiotherapy ,then followed by adjuvant therapy with tislelizumab(200mg) every three weeks for 13 cycles after radiotherapy
Study: NCT05328349

Intervention type: BEHAVIORAL
Intervention: Education Program
Description: After the baseline evaluation, all participants will take part in an education intervention, aiming at promoting self-management of shoulder pain, that will include two one-on-one sessions (approximately 30-45 minutes) within 2 weeks with a physiotherapist (1st session right after the baseline evaluation, 2nd session two weeks later). Participants will receive written information regarding shoulder (anatomy and function) and basic pain science and will be directed to watch a series of six educational videos on shoulder pain and function, persistent pain, physical activity, stress, sleep and eating habits. It should be noted that the objective of this study is not to assess the effectiveness of the intervention; the purpose of offering an intervention to participants is to control the intervention that will be received by them.
Study: NCT04932408

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the feasibility, psychosocial effects, influence and perception of exercise selection an experimental design of exercises performed at the hip and chest region.
Description: A single exposure feasibility study using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the feasibility, psychosocial effects, influence and perception of exercise selection an experimental design of exercises performed at the hip and chest region.
Description: A single exposure feasibility study using elastic resistance bands in older adults to challenge stability. Exercises with an elastic resistance band anchored from the ground and placed at the hip and chest region will be trialled. A semi- structured interview will identify the impact and practicalities of the intervention. The information will be used in the development of an evaluation process with key consideration of the planning phase of the intervention. Questions with verbal cues to provide perceptions of the exercise selection such as likes/dislikes, safety, confidence, difficulty, enjoyment and band placement will be asked to determine the acceptability, accessibility, appropriateness and usability of the protocol and build insights into the participant preferences.
Study: NCT05767268

Intervention type: DEVICE
Intervention: Lokomat
Description: gait rehabilitation
Study: NCT05227040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nintendo Ring Fit Adventure Exergame
Description: Participants in the RFA group were required to exercise for 30 minutes three times per week (in adventure mode) for 4 weeks. The initial exercise intensity was set according to the instructions given by the virtual coach during the first game and was gradually adjusted according to the game instructions. The research continued to track the RFA group subjects and continued to encourage the completion of 4 weeks of physical activity training.
Study: NCT04066907

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Integrated Disease Management
Description: Multidisciplinary intervention comprising of patient education, self management strategies and medication optimization
Study: 35341362

Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg/mL
Number of subjects: 430

Group type: COMPARATOR
Intervention: Dexamethasone 1 mg/mL
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Prior vomiting
Number of subjects: 430
Study: 33822385

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 0.5 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 2.0 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asfotase alfa 3.0 mg/kg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (0.5, 2.0, or 3.0 mg/kg) administered 3 times per week
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (dose-normalized exposure)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Asfotase alfa (dose-normalized exposure across BMI categories)
Number of subjects: 27
Study: 33244316

Group type: EXPERIMENTAL
Intervention: MVA recombinant vaccine expressing HIV-B antigen (MVA-B) via transcutaneous route
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MVA recombinant vaccine expressing HIV-B antigen (MVA-B) via intramuscular route
Number of subjects: 20
Study: 35382694

Group type: EXPERIMENTAL
Intervention: Comic
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Lay summary
Number of subjects: 1236

Group type: EXPERIMENTAL
Intervention: Scientific abstract
Number of subjects: 1236
Study: 32404980

Group type: EXPERIMENTAL
Intervention: Dietary intervention (specifics not provided)
Number of subjects: 609
Study: 36413516

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (Body in Mind Training [BMT])
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Fluoxetine (FLX)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Active control group (quality of life [QoL])
Number of subjects: 124
Study: 34188144

Group type: EXPERIMENTAL
Intervention: Inefficient arsenic metabolism (%iAs) among never-smokers
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Inefficient arsenic metabolism (%MMA) among never-smokers
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Efficient arsenic metabolism (%DMA) among never-smokers
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Inefficient arsenic metabolism (%iAs) among ever-smokers
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Inefficient arsenic metabolism (%MMA) among ever-smokers
Number of subjects: 1395

Group type: EXPERIMENTAL
Intervention: Efficient arsenic metabolism (%DMA) among ever-smokers
Number of subjects: 1395
Study: 32471934

Group type: EXPERIMENTAL
Intervention: Reference ranges based on dyspnoea percentiles (0‐10 Borg scale) established in 275 apparently healthy subjects aged 20‐85 years (131 men).
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Subjects with physiological abnormalities known to elicit exertional dyspnoea.
Number of subjects: 167

Group type: COMPARATOR
Intervention: Validation sample (n=451; 224 men) compared with reference sample.
Number of subjects: 167
Study: 35752525

Group type: EXPERIMENTAL
Intervention: SGA with preemptive AWNB
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: SGA with preemptive LAI
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard General Anesthesia (SGA)
Number of subjects: 90
Study: 32170589

Group type: EXPERIMENTAL
Intervention: Inpatient pharmaceutical care (medication reconciliation, daily pharmacist visits, discharge counseling and education by 2 certified pharmacists)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Inpatient pharmaceutical care
Number of subjects: 61
Study: 35859500

Group type: EXPERIMENTAL
Intervention: Plusoptix
Number of subjects: 2910

Group type: EXPERIMENTAL
Intervention: 2WIN Adaptica
Number of subjects: 2910

Group type: COMPARATOR
Intervention: Mohindra retinoscopy
Number of subjects: 2910
Study: 34079243

Group type: EXPERIMENTAL
Intervention: Tai Ji Quan
Number of subjects: 30

Group type: COMPARATOR
Intervention: Stretching
Number of subjects: 30
Study: 32470312

Group type: EXPERIMENTAL
Intervention: NMES+PRO (neuromuscular electrical stimulation combined with protein supplementation)
Number of subjects: 16

Group type: COMPARATOR
Intervention: CON (control group)
Number of subjects: 16
Study: 35410947

Group type: EXPERIMENTAL
Intervention: Febuxostat treatment
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 204
Study: 33646060

Group type: EXPERIMENTAL
Intervention: PRP-FG dressing plus oral vitamin E and C
Number of subjects: 25

Group type: COMPARATOR
Intervention: PRP-FG dressing plus placebo
Number of subjects: 25
Study: 32876328

Group type: EXPERIMENTAL
Intervention: Teriparatide 20 mcg
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Teriparatide
Number of subjects: 41
Study: 33955249

Group type: EXPERIMENTAL
Intervention: Right arm CGM placement
Number of subjects: 46

Group type: COMPARATOR
Intervention: Left arm CGM placement
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Intermittent fasting diet
Number of subjects: 46

Group type: COMPARATOR
Intervention: Free-living diet
Number of subjects: 46
Study: 34798031

Group type: EXPERIMENTAL
Intervention: Intervention (PrEP delivery integrated in public HIV care clinics)
Number of subjects: 4898
Study: 32213642

Group type: EXPERIMENTAL
Intervention: 100 mg daily aspirin
Number of subjects: 19114

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19114
Study: 35931830

Group type: EXPERIMENTAL
Intervention: Pediguard system
Number of subjects: 20

Group type: COMPARATOR
Intervention: Free-hand control group
Number of subjects: 20
Study: 36029335

Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (XCM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (SCTG)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: XCM
Number of subjects: 30

Group type: COMPARATOR
Intervention: SCTG
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 30
Study: 33539426

Group type: EXPERIMENTAL
Intervention: Cooperative groups (goal sharing)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Independent groups (non‐goal sharing)
Number of subjects: 26
Study: 35128668

Group type: EXPERIMENTAL
Intervention: Similarity graph algorithm with a 1.5% criterion of similarity and a time window of 2-5 s
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Traditional IBI analyses
Number of subjects: 73
Study: 34477316

Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 20

Group type: COMPARATOR
Intervention: Spironolactone
Number of subjects: 20
Study: 33259459

Group type: EXPERIMENTAL
Intervention: Open-label placebo (OLP)
Number of subjects: 55
Study: 32471387

Group type: EXPERIMENTAL
Intervention: Developmental and Sequenced One‐to‐One Intervention (DS1‐EI)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU)
Number of subjects: 72
Study: 36070046

Group type: EXPERIMENTAL
Intervention: Subthreshold pan-retinal photocoagulation (S-PRP)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Threshold pan-retinal photocoagulation (T-PRP)
Number of subjects: 35
Study: 32914716

Group type: EXPERIMENTAL
Intervention: Auto-segmentation using FCN-8s network architecture
Number of subjects: 121

Group type: COMPARATOR
Intervention: Auto-segmentation treating CTV as one anatomical region
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Auto-segmentation treating two parts of CTV as independent regions
Number of subjects: 121

Group type: COMPARATOR
Intervention: Auto-segmentation
Number of subjects: 121
Study: 34058948

Group type: EXPERIMENTAL
Intervention: IM20 × 4
Number of subjects: 273

Group type: EXPERIMENTAL
Intervention: IM60 × 4
Number of subjects: 273

Group type: COMPARATOR
Intervention: IM20 × 3
Number of subjects: 273
Study: 35565689

Group type: EXPERIMENTAL
Intervention: PFO‐SM (1% PFO, 180 mL/serving)
Number of subjects: 48

Group type: COMPARATOR
Intervention: SM (Soybean Milk, 180 mL/serving)
Number of subjects: 48

Group type: COMPARATOR
Intervention: BS‐SM (Black Sesame-Soybean Milk, 180 mL/serving)
Number of subjects: 48
Study: 34526698

Group type: EXPERIMENTAL
Intervention: mRNA-1273 booster
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: mRNA-1273.211 booster
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Variant-modified boosters
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All boosters (including mRNA-1273)
Number of subjects: 80
Study: 36320174

Group type: EXPERIMENTAL
Intervention: Betahistine 24 mg every 12 hours for 90 days
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo tablets every 12 hours for 90 days
Number of subjects: 62
Study: 35397165

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/d, n=40)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Metformin (1700 mg/d, n=36)
Number of subjects: 76
Study: 34615520

Group type: EXPERIMENTAL
Intervention: Lower relative physical capacity group
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Higher relative physical capacity group
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Higher relative physical capacity group (multivariate analysis)
Number of subjects: 298
Study: 32735552

Group type: EXPERIMENTAL
Intervention: E2V/LNG IUS
Number of subjects: 79

Group type: COMPARATOR
Intervention: E2/NETA
Number of subjects: 79

Group type: COMPARATOR
Intervention: CEE/MPA
Number of subjects: 79
Study: 34694249

Group type: EXPERIMENTAL
Intervention: US-guided steroid injection targeting both subcompartments (APL and EPB)
Number of subjects: 50

Group type: COMPARATOR
Intervention: US-guided steroid injection targeting the EPB subcompartment alone
Number of subjects: 50

Group type: COMPARATOR
Intervention: Comparison of skin hypopigmentation between groups
Number of subjects: 50
Study: 32804839

Group type: EXPERIMENTAL
Intervention: Single-step multiple transluminal gateway drainage (MTGD) using two lumen-apposing metal stents (LAMSs)
Number of subjects: 6
Study: 35068322

Group type: EXPERIMENTAL
Intervention: Home-based cardiac rehabilitation provided by primary care physiotherapists
Number of subjects: 8
Study: 33439435

Group type: COMPARATOR
Intervention: Educational eligibility for Autism services
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: Autism Diagnostic Observation Schedule, second edition (ADOS-2) classification
Number of subjects: 283
Study: 33036537

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS) for 30 minutes once daily for 30 days
Number of subjects: 58
Study: 35866144

Group type: EXPERIMENTAL
Intervention: MTA (2 mm)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Biodentine (3 mm)
Number of subjects: 52
Study: 33078518

Group type: EXPERIMENTAL
Intervention: Verum tDCS (anodal-1 mA for 20 min)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Sham tDCS (anodal-1 mA for 30 sec)
Number of subjects: 23
Study: 33208652

Group type: EXPERIMENTAL
Intervention: 2% lidocaine gel
Number of subjects: 128

Group type: COMPARATOR
Intervention: Water-based lubricant
Number of subjects: 128
Study: 32032094

Group type: EXPERIMENTAL
Intervention: Xenon (0.25, 0.50, and 0.75 MACawake; 1.30 MACawake for loss of responsiveness)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (0.25, 0.50, and 0.75 MACawake)
Number of subjects: 21
Study: 36085384

Group type: EXPERIMENTAL
Intervention: MAT-2P-LC (2-port laparoscopic cholecystectomy assisted by magnetic anchor technique)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 3P-LC (conventional 3-port laparoscopic cholecystectomy)
Number of subjects: 60